Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.
Also called NCT03252665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT03252665
-
- Other papers using this trial's data
- Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03252665. Randomized; single masking; primary purpose treatment. Start 2017-09-01 (anticipated); primary completion 2019-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
- Condition
- ST Segment Elevation Myocardial Infarction
- Intervention (Drug)
- Alprostadil
- Intervention (Drug)
- Nicorandil
- Intervention (Drug)
- Nitroglycerin
- Lead sponsor
- RenJi Hospital
- Collaborator
- Shanghai 10th People's Hospital
- Collaborator
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator
- Shanghai 6th People's Hospital
- Collaborator
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator
- Ruijin Hospital
Record details
- Record id
cardio:ct-nct03252665- Content hash
966d88534005f626a112fe49f157d321d39ced2b04751634c05c2a346adf362d